^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | INCB57643 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
Excerpt:
To investigate more effective therapeutic regimens, we first evaluated the cytotoxicity of INCB057643 in 8 MYC-driven (MYC-R or Mychigh) DLBCL cell lines, including 4 lines with Mut-TP53 (2 lines also had BCL2-R)...These cell lines were highly sensitive to INCB057643 treatment...They all showed increased apoptosis after INCB057643 treatment...
DOI:
10.1158/1541-7786.MCR-20-0466
